Get to Know Arjuna: New molecule for metastatic cancers with limited therapeutic options
Get to Know Arjuna: New molecule for metastatic cancers with limited therapeutic options
Arjuna, a spin-out from the University of Santiago de Compostela, is pioneering a new treatment modality with transformative potential. Its lead drug, Ag5, targets cancer cell's mitochondria to prevent metastasis, treat drug-resistant cancers, and address critical unmet needs in oncology, with ambitions to expand its impact beyond cancer in the future.
This session is tailored for doctors, researchers, investors, and healthcare enthusiasts, offering a deep dive into Arjuna's groundbreaking cancer treatment approach and its potential to transform oncology care.
Explore the details: https://capitalcell.com/en/campaign/arjuna-therapeutics-2024/
What will we cover in these sessions?
What is Arjuna?
Discover the team behind Arjuna, their mission, current progress, and future plans.
Why is this project so relevant?
Dr. Frederik De Smet, a renowned cancer biologist with over 13 years of experience, has dedicated his career to advancing cancer research and developing innovative therapeutics. His expertise spans collaborations with leading international institutions and pharmaceutical companies, translating novel concepts into impactful drug discovery programs. As a pioneer in patient-derived models for high-grade brain cancers like glioblastoma and advanced single-cell analysis techniques, Dr. De Smet offers invaluable insights into oncology. During the webinar, he will share his testimonial, highlighting the transformative potential of Arjuna’s Ag5 technology and its groundbreaking approach to addressing unmet needs in cancer treatment.
Q&A Session
Get answers to your questions about Capital Cell, how it works, and how you can be part of this journey.
Spread the Word
Share this webinar with your network to help advance the future of tissue transplants. See you soon!